Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.78
-$0.11(-3.01%)
At close: 4:00 PM EST
$0.78
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.54 - $6.18
Previous CloseN/A
Volume8.73K
Average Volume (3M)101.31K
Market Cap
$2.09M
Enterprise Value$1.34M
Total Cash (Recent Filing)$989.00K
Total Debt (Recent Filing)$2.36M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.74
Shares Outstanding3,535,489
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit-0.79
Enterprise Value/Ebitda0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Leverage & EquityMaterial debt reduction and a return to positive equity improve solvency and financing optionality over the next 2–6 months. Lower leverage reduces refinance and covenant risk, giving management more time to advance clinical programs or pursue non-dilutive funding before raising equity.
Expanded CDMO Footprint & Strategic PactAcquiring Recipharm Israel and a strategic commercial collaboration meaningfully broadens manufacturing scope and technical depth. A two-site CDMO platform with pre-agreed transfer frameworks supports durable service revenue potential and better client retention across development-to-commercial transitions.
Access To Non-Dilutive R&D FundingPursuing €12M of non-repayable grant funding to co-finance PC111 R&D would advance first-in-human proof-of-concept while preserving equity. Successful non-dilutive financing materially improves runway and allows clinical progress without immediate shareholder dilution, a durable financing lever.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing funding needs. Even with improvement versus 2023, continued cash consumption will require recurring financing or grant support; persistent burn constrains R&D pacing and capital allocation for 2–6 months ahead.
Negative Gross Profit & Operating LossesSustained negative gross margins and large operating losses indicate structural profitability issues in current operations. Until scale, higher-margin CDMO revenues, or pipeline milestones materialize, the firm will struggle to generate durable profits and must rely on external funding.
Nasdaq Minimum Bid Price DeficiencyA listing compliance deficiency creates material execution risk: potential delisting would impair U.S. capital access and liquidity. Addressing the deficiency may force dilutive financings or costly interventions, constraining strategic flexibility and partner confidence over coming months.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.54 and its highest was $6.18 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $2.09M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is May 07, 2026 which is in 18 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Dec 02, 2025. The company reported -$4.742 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.742.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,535,489 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$4.742 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Technical Analysis
Ownership Overview
―
Insiders
0.46% Other Institutional Investors
99.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---